A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part
第一作者机构：[1]Capital Med Univ, Beijing Tongren Hosp, Dept Hematol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Lei,Li Xin,Cong Jia,et al.A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part[J].BLOOD.2024,144:6413-6413.doi:10.1182/blood-2024-207469.
APA：
Yang, Lei,Li, Xin,Cong, Jia&Wang, Liang.(2024).A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part.BLOOD,144,
MLA：
Yang, Lei,et al."A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part".BLOOD 144.(2024):6413-6413
医学